Acrivon Therapeutics (ACRV) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Acrivon Therapeutics (ACRV) over the past year, gaining 128.0% versus a loss of 2.6%. Neuraxis is the larger company by market cap ($87.0 million vs $81.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | NRXS |
|---|---|---|
| Share price | $1.91 | $6.93 |
| Market cap | $81.85M | $87.03M |
| 1-day change | +2.14% | +2.36% |
| YTD return | -20.75% | +52.64% |
| 1-year return | -2.55% | +127.96% |
| EPS (TTM) | $-1.91 | $-0.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $9.33 |
| 52-week low | $1.27 | $2.21 |
| Distance from 52-week high | -46.35% | -25.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +502.09% | +58.73% |
| Average volume | 356.18K | 108.37K |
| Shares outstanding | 42.85M | 12.56M |
| Employees | 74 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed ACRV by 130.5 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
ACRV vs NRXS FAQ
Which is bigger, Acrivon Therapeutics or Neuraxis?
Neuraxis (NRXS) is larger, with a market capitalization of $87.03M compared with $81.85M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or NRXS?
NRXS returned +127.96% over the past 12 months, compared with -2.55% for ACRV (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Neuraxis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Acrivon Therapeutics and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Neuraxis.